Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.

Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; IDEAL Investigators.

J Am Coll Cardiol. 2009 Dec 15;54(25):2353-7. doi: 10.1016/j.jacc.2009.08.035.

3.

Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).

Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M.

Am J Cardiol. 2010 Aug 1;106(3):354-9. doi: 10.1016/j.amjcard.2010.03.033.

PMID:
20643245
4.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
5.

Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.

Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.

Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):315-20. doi: 10.1097/HJR.0b013e32832130f5.

PMID:
19322096
6.

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).

Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators.

Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029. Epub 2009 Jan 17.

PMID:
19231315
7.

Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).

Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL.

Am J Cardiol. 2011 Jan 15;107(2):145-50. doi: 10.1016/j.amjcard.2010.09.006. Epub 2010 Dec 2.

PMID:
21129718
8.

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E.

Circulation. 2006 Mar 21;113(11):1406-14. Epub 2006 Mar 13.

10.
11.

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E.

J Am Coll Cardiol. 2006 Aug 1;48(3):438-45. Epub 2006 Jul 12.

12.

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators.

J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.

13.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
15.

Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Clin Ther. 2008 Jan;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

PMID:
18343257
16.

Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).

LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, Breazna A; TNT Investigators.

Am J Cardiol. 2010 Feb 1;105(3):283-7. doi: 10.1016/j.amjcard.2009.09.025. Epub 2009 Dec 22.

PMID:
20102935
18.

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.

Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ.

Am Heart J. 2008 Oct;156(4):698-705. doi: 10.1016/j.ahj.2008.05.032. Epub 2008 Sep 5.

PMID:
18926150
19.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.

20.

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.

Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.

Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16.

PMID:
25595417
Items per page

Supplemental Content

Write to the Help Desk